View ValuationIntegral Diagnostics 将来の成長Future 基準チェック /36Integral Diagnostics利益と収益がそれぞれ年間27.6%と6.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に9.8% 28.1%なると予測されています。主要情報27.6%収益成長率28.15%EPS成長率Healthcare 収益成長19.8%収益成長率6.4%将来の株主資本利益率9.76%アナリストカバレッジGood最終更新日30 Jun 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 25+ 1 more updateIntegral Diagnostics Limited Announces Executive ChangesIntegral Diagnostics Limited announced referred to its market release on 10 November 2025 announcing the appointment of Jason Martinez as the Company's new Managing Director and Chief Executive Officer. That release noted that Mr. Martinez's commencement date would subsequently be confirmed to the market. IDX advises that Mr. Martinez will commence in his role with IDX on 6 August 2026, following an extended garden leave period with his former employer. Dr Ian Kadish will continue serving as Managing Director and Chief Executive Officer until Mr. Martinez commences to ensure a seamless leadership transition for IDX.お知らせ • Feb 25+ 1 more updateIntegral Diagnostics Limited Declares A Franked Ordinary Dividend for the Six-Month Period Ended 31 December 2025, Payable on 2 April 2026Integral Diagnostics Limited has declared a franked ordinary dividend of AUD 0.033 per share for the six-month period ended 31 December 2025. The ex-date for the dividend is 4 March 2026, the record date is 5 March 2026, and the payment date is scheduled for 2 April 2026.お知らせ • Jan 15+ 1 more updateIntegral Diagnostics Limited to Report Fiscal Year 2026 Results on Aug 25, 2026Integral Diagnostics Limited announced that they will report fiscal year 2026 results on Aug 25, 2026お知らせ • Sep 02Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025.お知らせ • Mar 11Private Equity Players Reportedly Keep Close Tabs on Integral DiagnosticsIntegral Diagnostics Limited (ASX:IDX) is believed once again to be in the spotlight for private equity buyers after its share price took a hit after its half year results, trimming its market value to $837 million. Sources say the diagnostic imaging company is constantly being assessed by private equity firms, eager to increase exposure to healthcare. But right now it is looking like a good buying opportunity and is grabbing attention. Obvious suitors would be the underbidders from the sale last year of the Healius diagnostic imaging group that sold for $965 million to Affinity Equity Partners. The underbidders were TPG Capital, L.P. and Pacific Equity Partners.お知らせ • Feb 05Integral Diagnostics Limited Appoints Manish Mittal to the Board as Radiologist Executive DirectorIntegral Diagnostics Limited announced the appointment of experienced IDX radiologist Dr. Manish Mittal (MBBS (Hons), MD, FRCR, FRANZCR, FSCMR) to the Board as a Radiologist Executive Director with effect from 5 February 2025. Mittal is a Fellow of both the UK and Australia & New Zealand Royal Colleges of Radiology with a professional focus on MRI, including musculoskeletal, prostrate and cardiac imaging in addition to extensive experience in neuroradiology and abdominal radiology. Dr. Mittal has worked within IDX and its precursor businesses for over 18 years and held senior clinical governance and leadership roles across a number of IDX business units. He is currently the Clinical Director of IDXt, IDX's fast growing teleradiology business, and also a consultant radiologist at Gold Coast University Hospital.お知らせ • Jan 20Integral Diagnostics Limited Announces Company Secretary ChangesIn accordance with Listing Rule 3.16, Integral Diagnostics Limited announced that effective 20 January 2025, Mr. John Merity has been appointed as company's permanent Company Secretary, continuing from the interim role to which he was appointed on 7 June 2024. Also effective from 20 January 2025, Ms Nikki Dalla Valle will relinquish her role as Company Secretary, continuing in her role as General Counsel, responsible for Legal and Risk.お知らせ • Dec 20Integral Diagnostics Limited Announces Board AppointmentsIntegral Diagnostics Limited has appointed the following Capitol Directors to the Integral Board with effect from 20 December 2024. Laura McBain, as Non-Executive Director; and Dr Kevin Shaw, as Non-Executive Director. Ms McBain has extensive executive and leadership experience having held roles as Managing Director at Bellamy's Australia, Maggie Beer Holdings and Lark Distilling. Dr Shaw is a highly qualified radiologist with fellowship training in MRI. He is the Director of Medical Imaging at University Hospital Geelong.お知らせ • Dec 12Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ).Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million on June 17, 2024. The consideration consists of common equity of Integral Diagnostics Limited at a ratio of 0.12849 per common equity of Capitol Health Limited. As per the transaction, Integral and Capitol shareholders would be expected to own approximately 63% and 37% respectively of the combined entity. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders, due diligence investigation and subject to court approval. As of October 29, 2024, Capitol announces that the Federal Court of Australia (Court) has today made orders to postpone the date of the Scheme Meeting at which Capitol Shareholders will vote on the proposed Scheme. The Scheme Meeting has been postponed from October 31, 2024 to December 2, 2024. The date for the Second Court Hearing has been changed from November 1, 2024 to December 4, 2024. As a consequence of the Court orders postponing the Scheme Meeting, the indicative Effective Date on which the Scheme comes into effect and is binding on Capitol Shareholders will be on December 5, 2024. As of November 25, 2024, the Scheme is subject to a number of conditions precedent, including that IDX has received informal merger clearance from the Australian Competition and Consumer Commission (ACCC). The ACCC has delayed its proposed decision date in relation to the Competition Approval to allow the ACCC to consider the divestment. The ACCC has not yet announced a new proposed date of its decision in relation to the Competition Approval, although Capitol anticipates that the decision date will occur in December 2024. The Scheme Meeting will proceed on December 2, 2024. As of December 10, 2024, the Australian Competition and Consumer Commission confirmed that it will not oppose the merger and the Federal Court of Australia made orders approving the Scheme. The deal is expected to complete on December 11, 2024. Barrenjoey Capital Partners and Jefferies (Australia) Pty Ltd acted as financial advisors to Integral Diagnostics Limited (ASX:IDX) while Citigroup Global Markets Australia Pty Limited acted as a financial advisor to Capitol Health Limited. Herbert Smith Freehills acted as a legal advisor to Integral Diagnostics Limited while Maddocks Inc. Pty Ltd. provided legal assistance to Capitol Health Limited. KPMG Financial Advisory Services (Australia) Pty Limited provided fairness opinion in the deal to Capitol Health Limited. Computershare Investor Services Pty Limited acted as registrar to Integral Diagnostics Limited and Capitol Health Limited. Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ) on December 11, 2024.お知らせ • Nov 08+ 1 more updateIntegral Diagnostics Limited to Report Fiscal Year 2025 Results on Aug 26, 2025Integral Diagnostics Limited announced that they will report fiscal year 2025 results on Aug 26, 2025お知らせ • Jun 19Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million on June 17, 2024. The consideration consists of common equity of Integral Diagnostics Limited at a ratio of 0.12849 per common equity of Capitol Health Limited. As per the transaction, Integral and Capitol shareholders would be expected to own approximately 63% and 37% respectively of the combined entity. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders, due diligence investigation and subject to court approval. Barrenjoey Capital Partners and Jefferies (Australia) Pty Ltd acted as financial advisors and Herbert Smith Freehills acted as legal advisor to Integral Diagnostics Limited. Citigroup Global Markets Australia Pty Limited acted as financial advisor and Maddocks Inc. Pty Ltd. acted as legal advisor to Capitol Health Limited.お知らせ • Feb 07IDX™ Announces Appointment of Scott Paterson as Worldwide CFOIDX™ announced the appointment of industry veteran Scott Paterson as chief financial officer. In his role, Paterson will partner with Worldwide CEO Myles Peacock and the IDX Board of Directors to continue the growth and evolution of the business. Paterson has held various senior finance roles for over 15 years, with many spent in marketing content, communications and technology. Prior to joining IDX, Paterson was CFO of private equity-backed TREND Networks, where he played a key role in the growth of the organization. He subsequently led the business through a private equity exit. Prior to TREND Networks, Paterson was group financial controller at Guinness World Records, where he was integral in transforming the business from its publishing core to a more diversified media enterprise focused on content creation and both digital and broadcast media. Paterson’s appointment is effective immediately.お知らせ • Dec 20+ 2 more updatesIntegral Diagnostics Limited, Annual General Meeting, Nov 01, 2024Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024.お知らせ • Dec 12Integral Diagnostics Limited Announces Change of Company SecretaryIntegral Diagnostics Limited advised that Kirsty Lally has resigned as Company Secretary of Integral Diagnostics Limited effective 14 December 2023. Nikki Dalla Valle has been appointed as Company Secretary effective 14 December 2023 and is the person nominated under Listing Rule 12.6 for communication with ASX in relation to Listing Rule matters.お知らせ • Nov 30Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023Integral Diagnostics Limited announced resignation of Helen Kurincic as director effective 29 November 2023.お知らせ • Sep 28Integral Diagnostics Limited Appoints Toby Hall as DirectorIntegral Diagnostics Limited announced that the appointment of Toby Hall as director. The date of appointment is September 28, 2023.お知らせ • Sep 25Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023Integral Diagnostics Limited declared a fully franked final dividend of AUD 0.03500000 per ordinary share for the six months ended June 30, 2023 with a record date of 1 September 2023. Ex date of August 31, 2023.Payable on 4 October 2023.お知らせ • Aug 28Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023On 28 August 2023 the directors of Integral Diagnostics Limited declared a fully franked final dividend of 3.5 cents per ordinary share with a record date of 1 September 2023 to be paid on 4 October 2023.お知らせ • Aug 10Integral Diagnostics Limited Announces Board ChangesIntegral Diagnostics Limited announced the appointment of Ingrid Player as an independent non-executive Director, effective 29 August 2023. Ms. Player has more than 20 years' experience in the healthcare industry, gained from leadership roles across the private, public and not for profit sectors. In her executive career, Ms. Player was Group Executive - Legal, Governance and Sustainability at Healthscope. As a qualified lawyer, she previously worked in private legal practice in Australia and Europe specialising in corporate law, M&A and capital markets. She brings to the Board extensive experience in leveraging corporate transactions and major capital projects to achieve strategic outcomes, as well as skills in risk management, government relations, sustainability and corporate governance. She currently serves as a Non-Executive Director of Cleanaway Management Ltd, Cogstate Ltd, Epworth Foundation and HealthShare Victoria. She holds a Bachelor of Laws (Hons) and Bachelor of Economics from Monash University and is a member of the AICD. She will be appointed a Member of the Audit, Risk & Compliance Committee and a Member of the People, Culture & Remuneration Committee. The company announced the resignation of John Atkin as an independent non-executive Director effective 31 August 2023. The company also announced the resignation of Dr. Nazar Bokani, an Executive Radiologist Director effective 9 August 2023. Dr. Bokani joined the Board on 26 April 2021 and is relocating overseas to be closer to his family.お知らせ • Feb 18Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023Integral Diagnostics Limited announced an ordinary dividend of AUD 0.025000 for the six months ended December 31, 2022. The ex-date is March 2, 2023, record date is March 3, 2023, and payment date is April 4, 2023.お知らせ • Feb 16Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023Integral Diagnostics Limited announced that they will report first half, 2023 results on Feb 17, 2023お知らせ • Jan 09Integral Diagnostics Limited, Annual General Meeting, Nov 03, 2023Integral Diagnostics Limited, Annual General Meeting, Nov 03, 2023.業績と収益の成長予測OTCPK:ITGD.F - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/2029977727615936/30/20289046270138116/30/20278535368131126/30/202680330481041212/31/2025768142785N/A9/30/202569892079N/A6/30/202562751474N/A3/31/202555952473N/A12/31/202449163473N/A9/30/2024481-283870N/A6/30/2024470-614266N/A3/31/2024463-592962N/A12/31/2023456-581658N/A9/30/2023449-162063N/A6/30/2023441252367N/A3/31/2023418232056N/A12/31/2022395211745N/A9/30/2022378181341N/A6/30/202236115937N/A3/31/2022361181441N/A12/31/2021360221844N/A9/30/2021356263457N/A6/30/2021351314970N/A3/31/2021333325473N/A12/31/2020315325976N/A9/30/2020295284465N/A6/30/2020276232854N/A3/31/2020263221947N/A12/31/201925021939N/A9/30/201924121N/A37N/A6/30/201923221N/A34N/A3/31/201922219N/A30N/A12/31/201821117N/A26N/A9/30/201820016N/A26N/A6/30/201818915N/A27N/A3/31/201818715N/A27N/A12/31/201718515N/A27N/A9/30/201718215N/A25N/A6/30/201718015N/A23N/A3/31/201717716N/A26N/A12/31/201617516N/A30N/A9/30/201617114N/A27N/A6/30/201616811N/A24N/A3/31/201616511N/A22N/A12/31/201516211N/A20N/A9/30/20151578N/A18N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ITGD.Fの予測収益成長率 (年間27.6% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: ITGD.Fの収益 ( 27.6% ) はUS市場 ( 18.4% ) よりも速いペースで成長すると予測されています。高成長収益: ITGD.Fの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: ITGD.Fの収益 ( 6.4% ) US市場 ( 12.7% ) よりも低い成長が予測されています。高い収益成長: ITGD.Fの収益 ( 6.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ITGD.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 9.8 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/07 18:48終値2026/07/02 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Integral Diagnostics Limited 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22 アナリスト機関Thomas YeoBarrenjoey Markets Pty LimitedSaul HadassinBarrenjoey Markets Pty LimitedBenjamin BrayshawBarrenjoey Markets Pty Limited19 その他のアナリストを表示
お知らせ • Mar 25+ 1 more updateIntegral Diagnostics Limited Announces Executive ChangesIntegral Diagnostics Limited announced referred to its market release on 10 November 2025 announcing the appointment of Jason Martinez as the Company's new Managing Director and Chief Executive Officer. That release noted that Mr. Martinez's commencement date would subsequently be confirmed to the market. IDX advises that Mr. Martinez will commence in his role with IDX on 6 August 2026, following an extended garden leave period with his former employer. Dr Ian Kadish will continue serving as Managing Director and Chief Executive Officer until Mr. Martinez commences to ensure a seamless leadership transition for IDX.
お知らせ • Feb 25+ 1 more updateIntegral Diagnostics Limited Declares A Franked Ordinary Dividend for the Six-Month Period Ended 31 December 2025, Payable on 2 April 2026Integral Diagnostics Limited has declared a franked ordinary dividend of AUD 0.033 per share for the six-month period ended 31 December 2025. The ex-date for the dividend is 4 March 2026, the record date is 5 March 2026, and the payment date is scheduled for 2 April 2026.
お知らせ • Jan 15+ 1 more updateIntegral Diagnostics Limited to Report Fiscal Year 2026 Results on Aug 25, 2026Integral Diagnostics Limited announced that they will report fiscal year 2026 results on Aug 25, 2026
お知らせ • Sep 02Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025.
お知らせ • Mar 11Private Equity Players Reportedly Keep Close Tabs on Integral DiagnosticsIntegral Diagnostics Limited (ASX:IDX) is believed once again to be in the spotlight for private equity buyers after its share price took a hit after its half year results, trimming its market value to $837 million. Sources say the diagnostic imaging company is constantly being assessed by private equity firms, eager to increase exposure to healthcare. But right now it is looking like a good buying opportunity and is grabbing attention. Obvious suitors would be the underbidders from the sale last year of the Healius diagnostic imaging group that sold for $965 million to Affinity Equity Partners. The underbidders were TPG Capital, L.P. and Pacific Equity Partners.
お知らせ • Feb 05Integral Diagnostics Limited Appoints Manish Mittal to the Board as Radiologist Executive DirectorIntegral Diagnostics Limited announced the appointment of experienced IDX radiologist Dr. Manish Mittal (MBBS (Hons), MD, FRCR, FRANZCR, FSCMR) to the Board as a Radiologist Executive Director with effect from 5 February 2025. Mittal is a Fellow of both the UK and Australia & New Zealand Royal Colleges of Radiology with a professional focus on MRI, including musculoskeletal, prostrate and cardiac imaging in addition to extensive experience in neuroradiology and abdominal radiology. Dr. Mittal has worked within IDX and its precursor businesses for over 18 years and held senior clinical governance and leadership roles across a number of IDX business units. He is currently the Clinical Director of IDXt, IDX's fast growing teleradiology business, and also a consultant radiologist at Gold Coast University Hospital.
お知らせ • Jan 20Integral Diagnostics Limited Announces Company Secretary ChangesIn accordance with Listing Rule 3.16, Integral Diagnostics Limited announced that effective 20 January 2025, Mr. John Merity has been appointed as company's permanent Company Secretary, continuing from the interim role to which he was appointed on 7 June 2024. Also effective from 20 January 2025, Ms Nikki Dalla Valle will relinquish her role as Company Secretary, continuing in her role as General Counsel, responsible for Legal and Risk.
お知らせ • Dec 20Integral Diagnostics Limited Announces Board AppointmentsIntegral Diagnostics Limited has appointed the following Capitol Directors to the Integral Board with effect from 20 December 2024. Laura McBain, as Non-Executive Director; and Dr Kevin Shaw, as Non-Executive Director. Ms McBain has extensive executive and leadership experience having held roles as Managing Director at Bellamy's Australia, Maggie Beer Holdings and Lark Distilling. Dr Shaw is a highly qualified radiologist with fellowship training in MRI. He is the Director of Medical Imaging at University Hospital Geelong.
お知らせ • Dec 12Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ).Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million on June 17, 2024. The consideration consists of common equity of Integral Diagnostics Limited at a ratio of 0.12849 per common equity of Capitol Health Limited. As per the transaction, Integral and Capitol shareholders would be expected to own approximately 63% and 37% respectively of the combined entity. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders, due diligence investigation and subject to court approval. As of October 29, 2024, Capitol announces that the Federal Court of Australia (Court) has today made orders to postpone the date of the Scheme Meeting at which Capitol Shareholders will vote on the proposed Scheme. The Scheme Meeting has been postponed from October 31, 2024 to December 2, 2024. The date for the Second Court Hearing has been changed from November 1, 2024 to December 4, 2024. As a consequence of the Court orders postponing the Scheme Meeting, the indicative Effective Date on which the Scheme comes into effect and is binding on Capitol Shareholders will be on December 5, 2024. As of November 25, 2024, the Scheme is subject to a number of conditions precedent, including that IDX has received informal merger clearance from the Australian Competition and Consumer Commission (ACCC). The ACCC has delayed its proposed decision date in relation to the Competition Approval to allow the ACCC to consider the divestment. The ACCC has not yet announced a new proposed date of its decision in relation to the Competition Approval, although Capitol anticipates that the decision date will occur in December 2024. The Scheme Meeting will proceed on December 2, 2024. As of December 10, 2024, the Australian Competition and Consumer Commission confirmed that it will not oppose the merger and the Federal Court of Australia made orders approving the Scheme. The deal is expected to complete on December 11, 2024. Barrenjoey Capital Partners and Jefferies (Australia) Pty Ltd acted as financial advisors to Integral Diagnostics Limited (ASX:IDX) while Citigroup Global Markets Australia Pty Limited acted as a financial advisor to Capitol Health Limited. Herbert Smith Freehills acted as a legal advisor to Integral Diagnostics Limited while Maddocks Inc. Pty Ltd. provided legal assistance to Capitol Health Limited. KPMG Financial Advisory Services (Australia) Pty Limited provided fairness opinion in the deal to Capitol Health Limited. Computershare Investor Services Pty Limited acted as registrar to Integral Diagnostics Limited and Capitol Health Limited. Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ) on December 11, 2024.
お知らせ • Nov 08+ 1 more updateIntegral Diagnostics Limited to Report Fiscal Year 2025 Results on Aug 26, 2025Integral Diagnostics Limited announced that they will report fiscal year 2025 results on Aug 26, 2025
お知らせ • Jun 19Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million on June 17, 2024. The consideration consists of common equity of Integral Diagnostics Limited at a ratio of 0.12849 per common equity of Capitol Health Limited. As per the transaction, Integral and Capitol shareholders would be expected to own approximately 63% and 37% respectively of the combined entity. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders, due diligence investigation and subject to court approval. Barrenjoey Capital Partners and Jefferies (Australia) Pty Ltd acted as financial advisors and Herbert Smith Freehills acted as legal advisor to Integral Diagnostics Limited. Citigroup Global Markets Australia Pty Limited acted as financial advisor and Maddocks Inc. Pty Ltd. acted as legal advisor to Capitol Health Limited.
お知らせ • Feb 07IDX™ Announces Appointment of Scott Paterson as Worldwide CFOIDX™ announced the appointment of industry veteran Scott Paterson as chief financial officer. In his role, Paterson will partner with Worldwide CEO Myles Peacock and the IDX Board of Directors to continue the growth and evolution of the business. Paterson has held various senior finance roles for over 15 years, with many spent in marketing content, communications and technology. Prior to joining IDX, Paterson was CFO of private equity-backed TREND Networks, where he played a key role in the growth of the organization. He subsequently led the business through a private equity exit. Prior to TREND Networks, Paterson was group financial controller at Guinness World Records, where he was integral in transforming the business from its publishing core to a more diversified media enterprise focused on content creation and both digital and broadcast media. Paterson’s appointment is effective immediately.
お知らせ • Dec 20+ 2 more updatesIntegral Diagnostics Limited, Annual General Meeting, Nov 01, 2024Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024.
お知らせ • Dec 12Integral Diagnostics Limited Announces Change of Company SecretaryIntegral Diagnostics Limited advised that Kirsty Lally has resigned as Company Secretary of Integral Diagnostics Limited effective 14 December 2023. Nikki Dalla Valle has been appointed as Company Secretary effective 14 December 2023 and is the person nominated under Listing Rule 12.6 for communication with ASX in relation to Listing Rule matters.
お知らせ • Nov 30Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023Integral Diagnostics Limited announced resignation of Helen Kurincic as director effective 29 November 2023.
お知らせ • Sep 28Integral Diagnostics Limited Appoints Toby Hall as DirectorIntegral Diagnostics Limited announced that the appointment of Toby Hall as director. The date of appointment is September 28, 2023.
お知らせ • Sep 25Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023Integral Diagnostics Limited declared a fully franked final dividend of AUD 0.03500000 per ordinary share for the six months ended June 30, 2023 with a record date of 1 September 2023. Ex date of August 31, 2023.Payable on 4 October 2023.
お知らせ • Aug 28Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023On 28 August 2023 the directors of Integral Diagnostics Limited declared a fully franked final dividend of 3.5 cents per ordinary share with a record date of 1 September 2023 to be paid on 4 October 2023.
お知らせ • Aug 10Integral Diagnostics Limited Announces Board ChangesIntegral Diagnostics Limited announced the appointment of Ingrid Player as an independent non-executive Director, effective 29 August 2023. Ms. Player has more than 20 years' experience in the healthcare industry, gained from leadership roles across the private, public and not for profit sectors. In her executive career, Ms. Player was Group Executive - Legal, Governance and Sustainability at Healthscope. As a qualified lawyer, she previously worked in private legal practice in Australia and Europe specialising in corporate law, M&A and capital markets. She brings to the Board extensive experience in leveraging corporate transactions and major capital projects to achieve strategic outcomes, as well as skills in risk management, government relations, sustainability and corporate governance. She currently serves as a Non-Executive Director of Cleanaway Management Ltd, Cogstate Ltd, Epworth Foundation and HealthShare Victoria. She holds a Bachelor of Laws (Hons) and Bachelor of Economics from Monash University and is a member of the AICD. She will be appointed a Member of the Audit, Risk & Compliance Committee and a Member of the People, Culture & Remuneration Committee. The company announced the resignation of John Atkin as an independent non-executive Director effective 31 August 2023. The company also announced the resignation of Dr. Nazar Bokani, an Executive Radiologist Director effective 9 August 2023. Dr. Bokani joined the Board on 26 April 2021 and is relocating overseas to be closer to his family.
お知らせ • Feb 18Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023Integral Diagnostics Limited announced an ordinary dividend of AUD 0.025000 for the six months ended December 31, 2022. The ex-date is March 2, 2023, record date is March 3, 2023, and payment date is April 4, 2023.
お知らせ • Feb 16Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023Integral Diagnostics Limited announced that they will report first half, 2023 results on Feb 17, 2023
お知らせ • Jan 09Integral Diagnostics Limited, Annual General Meeting, Nov 03, 2023Integral Diagnostics Limited, Annual General Meeting, Nov 03, 2023.